ACP
LJPC

Acuta Capital Partners’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Acuta Capital Partners’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-82,920
Closed -$2.24M – 65
2015
Q4 		$2.24M Sell
82,920
-39,302
-32% -$1.07M 1.07% 28
2015
Q3 		$3.4M Buy
+122,222
New +$3.85M 1.97% 15

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acuta Capital Partners's LJPC Position: Q1 2016 in Review

Acuta Capital Partners sold out of La Jolla Pharmaceutical Company (LJPC) in Q1 2016, closing a stake of 82,920 shares — an estimated $2.24M sold.

Acuta Capital Partners first reported a position in LJPC in Q3 2015 and held it in 2 quarters. The position peaked at $3.4M in Q3 2015. 70 funds tracked by Wall St. Rank hold LJPC as of Q1 2016.

  • Acuta Capital Partners reported no remaining La Jolla Pharmaceutical Company position as of Q1 2016 after selling out during the quarter.
  • Acuta Capital Partners sold 82,920 La Jolla Pharmaceutical Company shares in Q1 2016, an estimated $2.24M.
  • Acuta Capital Partners first reported a position in La Jolla Pharmaceutical Company in Q3 2015 and held it in 2 quarters.
  • Acuta Capital Partners's La Jolla Pharmaceutical Company position peaked at $3.4M in Q3 2015.
  • 70 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q1 2016.

Based on Acuta Capital Partners's 13F filing for Q1 2016, filed 13 May 2016.